Zeroing in on a cure

By Marilee Griffin

The UF Health Cancer Center has been named one of 12 initial clinical trial sites for Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. Starting in the spring of 2017, participants will enroll at a site and undergo advanced molecular profiling to determine their tumor’s unique molecular features, which will help match them to the substudy that best matches their needs. Patients will be monitored closely and follow-up analyses will provide important clues to help researchers understand the effectiveness of each treatment in real time. Through Precision Promise, an initiative of the national nonprofit organization Pancreatic Cancer Action Network, all data from the 12 sites will be analyzed together so findings can be disseminated in a timely manner.

Share this article with others:
  • E-mail this story to a friend!
  • Facebook
  • Digg
  • Twitter

November 2016

New CMO for UF Health Shands lauded for multifaceted career

Parker Gibbs Jr., M.D., brings a reputation for patient-centered care as well as national recognition for excellence in clinical orthopedic oncology to his new position as chief medical officer for UF Health Shands.

Don’t believe everything you read

Weight loss information on top Spanish-language websites unreliable, study shows

Losing their legs

Who knew snakes had limbs millions of years ago? UF researchers, that’s who

Musical stress relief

Dental students fill the UF Health Shands Atrium with calming classical notes

...also in this issue